Back to News
Market Impact: 0.3
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationM&A & Restructuring
Tempest Therapeutics announced an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform. The deal expands Tempest's technology access for developing in vivo CAR-T therapies targeting cancer and autoimmune disease, though no financial terms or development milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TPST0.45
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip
- How Ambani’s Jio became India’s second-largest company
- OpenAI pares fundraising goal, now seeking up to $20 billion in latest round